These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 36765099)
1. Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab. Matsumoto T; Ikoma T; Yamamura S; Miura K; Tsuduki T; Watanabe T; Nagai H; Takatani M; Yasui H Sci Rep; 2023 Feb; 13(1):2433. PubMed ID: 36765099 [TBL] [Abstract][Full Text] [Related]
2. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015 [TBL] [Abstract][Full Text] [Related]
3. Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis. Nakashima M; Takeuchi M; Tanaka S; Kawakami K Anticancer Res; 2021 Feb; 41(2):1055-1062. PubMed ID: 33517315 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study. Nakashima M; Takeuchi M; Kawakami K Clin Colorectal Cancer; 2020 Dec; 19(4):e208-e225. PubMed ID: 32912821 [TBL] [Abstract][Full Text] [Related]
5. Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. Oshima K; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Boku N PLoS One; 2022; 17(6):e0269115. PubMed ID: 35653412 [TBL] [Abstract][Full Text] [Related]
6. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856 [TBL] [Abstract][Full Text] [Related]
7. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883 [TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment. Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis. Basso M; Signorelli C; Calegari MA; Lucchetti J; Zurlo IV; Dell'Aquila E; Arrivi G; Zoratto F; Santamaria F; Saltarelli R; Trovato G; Caira G; Angotti L; Schirripa M; Anghelone A; Schietroma F; Chilelli MG; Salvatore L; Pozzo C; Tortora G Target Oncol; 2024 May; 19(3):371-382. PubMed ID: 38613732 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales. Bullement A; Underhill S; Fougeray R; Hatswell AJ Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922 [TBL] [Abstract][Full Text] [Related]
11. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932 [TBL] [Abstract][Full Text] [Related]
12. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis. Aquino de Moraes FC; Dantas Leite Pessôa FD; Duarte de Castro Ribeiro CH; Rodrigues Fernandes M; Rodríguez Burbano RM; Carneiro Dos Santos NP BMC Cancer; 2024 Jun; 24(1):674. PubMed ID: 38825703 [TBL] [Abstract][Full Text] [Related]
13. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590 [TBL] [Abstract][Full Text] [Related]
14. Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Paly VF; Dasari A; Hubbard J; Bekaii-Saab T; Padukkavidana T; Hernandez L J Comp Eff Res; 2024 Aug; 13(8):e240084. PubMed ID: 38976346 [No Abstract] [Full Text] [Related]
15. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). Kito Y; Kawakami H; Mitani S; Nishina S; Matsumoto T; Tsuzuki T; Shinohara Y; Shimokawa H; Kumanishi R; Ohta T; Katsuya H; Kawakami T; Nishina T; Hasegawa H; Akiyoshi K; Chiba Y; Yamazaki K; Hironaka S; Muro K Oncologist; 2024 Mar; 29(3):e330-e336. PubMed ID: 37950903 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review. Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864 [TBL] [Abstract][Full Text] [Related]
17. Improving survival in metastatic colorectal cancer through optimized patient selection. Bekaii-Saab TS; Barzi A; Cusnir M Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):1-20. PubMed ID: 38805297 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. Takahashi T; Yamazaki K; Oki E; Shiozawa M; Mitsugi K; Makiyama A; Nakamura M; Ojima H; Kagawa Y; Matsuhashi N; Okuda H; Asayama M; Yuasa Y; Shimada Y; Manaka D; Watanabe J; Oba K; Yoshino T; Yoshida K; Maehara Y ESMO Open; 2021 Apr; 6(2):100093. PubMed ID: 33744811 [TBL] [Abstract][Full Text] [Related]
19. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741 [TBL] [Abstract][Full Text] [Related]
20. Regorafenib and trifluridine/tipiracil in real clinical practice. García-Beloso N; Romero-Ventosa EY; Gayoso-Rey M; López-López A; Robles-Torres D; de Castro NM; Piñeiro-Corrales G J Cancer Res Ther; 2022 Dec; 18(Supplement):S367-S373. PubMed ID: 36510990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]